RT Journal Article
SR Electronic
T1 First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e006127
DO 10.1136/jitc-2022-006127
VO 11
IS 2
A1 Ready, Neal E
A1 Audigier-Valette, Clarisse
A1 Goldman, Jonathan W
A1 Felip, Enriqueta
A1 Ciuleanu, Tudor-Eliade
A1 Rosario García Campelo, María
A1 Jao, Kevin
A1 Barlesi, Fabrice
A1 Bordenave, Stéphanie
A1 Rijavec, Erika
A1 Urban, Laszlo
A1 Aucoin, Jean-Sébastien
A1 Zannori, Cristina
A1 Vermaelen, Karim
A1 Arén Frontera, Osvaldo
A1 Curioni Fontecedro, Alessandra
A1 Sánchez-Gastaldo, Amparo
A1 Juan-Vidal, Oscar
A1 Linardou, Helena
A1 Poddubskaya, Elena
A1 Spigel, David R
A1 Ahmed, Samreen
A1 Maio, Michele
A1 Li, Sunney
A1 Chang, Han
A1 Fiore, Joseph
A1 Acevedo, Angelic
A1 Paz-Ares, Luis
YR 2023
UL http://jitc.bmj.com/content/11/2/e006127.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.